|
|
|
 |
|
 |
KamRAB
(Human rabies immunoglobulin/HRIG)Indications
For passive, transient post-exposure prophylaxis of rabies infection
Characteristics
 |
Ready to use, preservative free solution in 2 ml, 5 ml and 10 ml vials |
|
Suitable for adults and children |
Status
|
FDA has approved the company's clinical program for Phase II-III clinical trials |
|
The product is registered and marketed in several countries around the world |
Profile
|
A sterile, ready-to-use solution of anti-rabies immune globulin. |
|
KamRab provides rapid immune protection. |
|
KamRab is administered in the following manner: at least half of the dose is infiltrated locally in and around the animal bite site the remainder is administered intramuscularly at a site removed from the wound |
According to CDC (Centers for Disease Control and Prevention) - an annual estimate of 55 thousand patients worldwide die each year following contact with a suspected rabid animal
|
|
|
|
|
More
|
